Wick Capital Partners LLC Acquires 55,878 Shares of Eli Lilly and Company (NYSE:LLY)

Wick Capital Partners LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 14,364.5% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 56,267 shares of the company’s stock after buying an additional 55,878 shares during the quarter. Eli Lilly and Company accounts for about 7.4% of Wick Capital Partners LLC’s holdings, making the stock its 4th biggest position. Wick Capital Partners LLC’s holdings in Eli Lilly and Company were worth $43,438,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Navigoe LLC acquired a new stake in shares of Eli Lilly and Company in the fourth quarter worth $77,000. Triumph Capital Management raised its stake in shares of Eli Lilly and Company by 15.1% in the 4th quarter. Triumph Capital Management now owns 1,376 shares of the company’s stock valued at $1,062,000 after buying an additional 180 shares in the last quarter. Connors Investor Services Inc. lifted its holdings in shares of Eli Lilly and Company by 8.7% during the 4th quarter. Connors Investor Services Inc. now owns 21,430 shares of the company’s stock worth $16,544,000 after acquiring an additional 1,709 shares during the period. Bridgewealth Advisory Group LLC raised its position in Eli Lilly and Company by 7.0% in the fourth quarter. Bridgewealth Advisory Group LLC now owns 246 shares of the company’s stock worth $190,000 after purchasing an additional 16 shares in the last quarter. Finally, Voleon Capital Management LP acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $5,665,000. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on LLY shares. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research note on Friday, January 17th. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Morgan Stanley dropped their price objective on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an “overweight” rating for the company in a report on Wednesday, April 9th. StockNews.com upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Finally, Cantor Fitzgerald began coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an “overweight” rating and a $975.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,000.32.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $885.54 on Wednesday. The business’s 50 day simple moving average is $828.13 and its two-hundred day simple moving average is $817.35. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a market capitalization of $839.64 billion, a P/E ratio of 75.62, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.